Physician
Chronic Pain Resources, LLC
Chronic Pain Resources, LLC was paid $2.60M by Medicaid between Jan 2018 and Aug 2022, across 50 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 51% of everything it billed.
33Billing provider infoCHRONIC PAIN RESOURCES, LLC
GROVE CITY, OH 43123
GROVE CITY, OH 43123
33aNPI1366697658assigned 12/01/2008
33bProvider typePain Medicine Physician
28Total paid$2.60M
24GClaims87,461
24DCodes billed50
24AFirst – last monthJan 2018 – Aug 2022
Compared with peers
Next to other Pain Medicine Physician providers in Ohio
Rank by total paid#1 of 16
Median peer was paid$112K
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,483 | $423K | |
| 2019 | 19,114 | $603K | |
| 2020 | 34,675 | $819K | |
| 2021 | 14,583 | $665K | |
| 2022 | 3,606 | $90K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 51% | 41,435 | 35,588 | $1.32M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 11% | 7,271 | 6,734 | $290K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 10% | 2,211 | 1,999 | $273K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.7% | 1,836 | 1,750 | $123K |
| 64483 | 2.3% | 1,021 | 689 | $59K | |
| 76000 | 2.2% | 1,775 | 1,693 | $58K | |
| 77002 | 1.8% | 1,015 | 718 | $47K | |
| 20610 | 1.6% | 1,064 | 750 | $42K | |
| L0627 | Lumbar orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | 1.6% | 327 | 320 | $41K |
| 80305 | 1.4% | 6,774 | 6,307 | $36K | |
| 64450 | <1% | 262 | 147 | $25K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 3,030 | 2,031 | $23K |
38 more codes
| 64493 | <1% | 591 | $22K | |
| 80346 | <1% | 576 | $13K | |
| 80363 | <1% | 577 | $11K | |
| 80361 | <1% | 574 | $11K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,545 | $11K |
| 64494 | <1% | 589 | $10K | |
| 64495 | <1% | 585 | $10K | |
| 83992 | <1% | 576 | $9K | |
| 62323 | <1% | 55 | $8K | |
| 27096 | <1% | 131 | $8K | |
| 80324 | <1% | 576 | $6K | |
| 80359 | <1% | 576 | $6K | |
| 80350 | <1% | 647 | $6K | |
| 80333 | <1% | 576 | $6K | |
| 80349 | <1% | 576 | $6K | |
| 80358 | <1% | 576 | $6K | |
| 80367 | <1% | 576 | $6K | |
| 80368 | <1% | 576 | $6K | |
| 80371 | <1% | 576 | $6K | |
| 80336 | <1% | 576 | $6K | |
| 80355 | <1% | 576 | $6K | |
| 80365 | <1% | 576 | $6K | |
| 80373 | <1% | 576 | $6K | |
| 80348 | <1% | 576 | $6K | |
| 80369 | <1% | 576 | $6K | |
| 80366 | <1% | 576 | $6K | |
| 80354 | <1% | 576 | $6K | |
| 80372 | <1% | 576 | $6K | |
| 80360 | <1% | 576 | $6K | |
| 80323 | <1% | 576 | $6K | |
| 64635 | <1% | 110 | $5K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 379 | $5K |
| 64636 | <1% | 115 | $4K | |
| 64640 | <1% | 16 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 63 | $3K |
| 80356 | <1% | 280 | $3K | |
| 64625 | <1% | 16 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 71 | $2K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMUKHDOMI, GULAM (PRESIDENT)